News

AdvaMed Medical Device Repeal Bill

Thursday, February 03, 2011

AdvaMed, the industry group representing medical device manufactures, largely supported the reform law but held reservations about the law's medical device tax. On Thursday, the group endorsed the bill repealing the tax, but it reiterated its support for the reform effort.

"While AdvaMed supports repeal of the excise tax, it remains committed to the central elements of health reform that are consistent with our long-held principles, including expanded coverage, reform of the payment system to encourage quality and efficiency, and a new emphasis on health promotion and disease prevention," AdvaMed President and CEO Stephen Ubl said in a statement. "As other proposed changes to the bill are considered by Congress, we will evaluate them in the light of these principles and their impact on patients and medical innovation.” 

InDevr signs global distributors

Wednesday, February 02, 2011

BOULDER, Colo. – February 1, 2011 – InDevR, one the West’s fastest growing biotechnology companies, today announced it has signed six agreements with leading life science instrument distributors for US and international territories to market the company’s ViroCyt™ 2100 Virus Counter®.  

BioScience Day at the Capitol Speakers

Wednesday, February 02, 2011

 

BioScience Day at the Capitol

Wednesday, February 02, 2011

Colorado's Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million 

BDEGP Creates 598 New Jobs in the State

Wednesday, February 02, 2011

 
Colorado's Bioscience Discovery Evaluation Grant Program Creates 598 New Jobs in the State, with Payroll Exceeding $44 million 

Colorado bioscience program creates 598 jobs

Wednesday, February 02, 2011

 

Colorado's Bioscience Discovery Evaluation Grant Program has created 598 jobs in the state, with payroll exceeding $44 million, according to the Colorado BioScience Association and the Colorado Office of Economic Development and International Trade.

Appropriated funding to date for the program has totaled $14 million; $10.8 million has been awarded as of August 2010, and $5.5 million has been appropriated for each of the next two years, said Holli Baumunk, the association's president and chief executive.

Another $68 million has been leveraged through follow-on investment, grants and matching funds, providing 8.3 times the state's funding, Baumunk said.

"Bioscience continues to play a critical role in the growth of Colorado's knowledge-based economy," Baumunk said.

http://www.denverpost.com/business/ci_17270132

Read more: Colorado bioscience program creates 598 jobs - The Denver Post http://www.denverpost.com/business/ci_17270132#ixzz1CpCa1k90
Read The Denver Post's Terms of Use of its content: http://www.denverpost.com/termsofuse  
Continue Reading

Boilerplate

Tuesday, February 01, 2011

About the Colorado BioScience Association
The Colorado BioScience Association (CBSA) is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 350 members, CBSA actively works to promote the growth of the industry by working for a better business environment, grow the state's biotech workforce, advocate for policies that support a strong bioscience industry in the state, and speak with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.  

Encision reports financials

Monday, January 31, 2011

Encision Inc. (Boulder) reported profitable financial results for its third fiscal quarter ended December 31, 2010.  The Company recorded net income of $234,000 or $0.04 per share for the third quarter of fiscal year 2011 on net sales of $2.917 million, representing a slight increase in net sales from our second quarter ended September 30, 2010, and a 10.5% decrease from net sales of $3.260 million for the third quarter of fiscal year 2010.
http://www.prnewswire.com/news-releases/encision-reports-profitable-third-quarter-results-114922199.html 

Taligen Therapeutics acquired for $111M

Monday, January 31, 2011

Taligen Therapeutics Inc. has been acquired by Alexion Pharmaceuticals Inc., a Connecticut therapeutics firm, for $111 million in an up front cash payment. 

CORHIO awarded $1.7M

Friday, January 28, 2011

CORHIO, the Colorado Regional Health Information Organization, has been awarded $1.7 million by the Health Information Exchange (HIE) Challenge Grant Program run by the Office of the National Coordinator for Health IT (ONC). CORHIO was selected for innovation in the area of care improvement and cost reduction for patients transitioning between hospitals, long-term care facilities and other post-acute care providers. The Challenge Grant allows CORHIO to support long-term and post-acute care providers in Boulder, Colorado Springs, Pueblo and the San Luis Valley as they work to implement processes to improve care transitions to and from hospitals in their communities.
http://www.prnewswire.com/news-releases/corhio-awarded-17m-grant-to-improve-care-coordination-for-hospital-and-long-term-care-patients-114816929.html